Synopsis:
The advent of biologic agents and Janus kinase (JAK) inhibitors has markedly advanced the treatment of rheumatoid arthritis (RA). Nonetheless, a proportion of patients continues to exhibit persistently high disease activity, representing a clinical challenge. In Japan, where the population is rapidly aging, long-term safety remains a paramount concern, underscoring the need for novel therapeutic approaches for patients with inadequate responses to existing treatments. Ozoralizumab, a next-generation tumor necrosis factor (TNF) inhibitor first approved in Japan, has gained attention as a promising agent. This bispecific antibody, utilizing a VHH domain, can bind both TNF and albumin. Our research shows that ozoralizumab is effective regardless of baseline rheumatoid factor (RF) levels and leads to reductions in both RF and anti-CCP antibodies. This symposium will highlight the therapeutic potential of ozoralizumab and discuss strategies for its optimal use in RA management.
Agenda:
|
|
Chairperson: Dr. Kunihiro Ichinose
|
|
TBA mins |
Presentation title TBA
Dr. Ryu Watanabe |
|
TBA mins |
Closing Remarks: Q&A and Discussion
All |
